Idiopathic Pulmonary Fibrosis (IPF): Global Clinical Trials Landscape

Novotech’s latest global market insights reveals a surge of innovation in Idiopathic Pulmonary Fibrosis (IPF) research.

Since 2020, over 800 industry-sponsored IPF trials have launched worldwide, reflecting robust momentum in addressing this serious condition.

Key highlights:
🔹 Asia-Pacific accounts for 44% of global IPF trial activity, primarily led by Mainland China.
🔹 Investigational therapies include RNA interference, PDE4 inhibitors, monoclonal antibodies, and cell-based treatments.
🔹 Precision trial designs and biomarker-driven methodologies are being increasingly adopted.
🔹 Funding from both private and public sectors continues to support innovation.
🔹 Racial and ethnic disparities in trial participation remain a concern across regions.

Download the full report to learn more about the evolving IPF clinical trial landscape.